4d Molecular Therapeutics, Inc. · NASDAQ:FDMT
Venrock Healthcare Capital Partners III, L.P. reported a 6.40% stake in 4d Molecular Therapeutics, Inc. (Schedule 13G/A)
Event Dec 31, 2024 · Filed Feb 14, 2025
Venrock Healthcare Capital Partners III, L.P. reported a 6.40% stake in 4d Molecular Therapeutics, Inc., 2,952,371 shares, as a passive investor on Dec 31, 2024. Filed Feb 14, 2025 (Schedule 13G/A).
- Stake
- 6.40%
- Shares
- 2,952,371
- Intent
- Passive
- What changed
- Stake changed
- Filed together
- 7 holders
The filing in full
| Holder | Stake | Shares |
|---|---|---|
| Venrock Healthcare Capital Partners III, L.P. | 6.40% | 2,952,371 |
| VHCP Co-Investment Holdings III, LLC | 6.40% | 2,952,371 |
| Venrock Healthcare Capital Partners EG, L.P. | 6.40% | 2,952,371 |
| VHCP Management III, LLC | 6.40% | 2,952,371 |
| VHCP Management EG, LLC | 6.40% | 2,952,371 |
| Nimish Shah | 6.40% | 2,952,371 |
| Bong Y Koh | 6.40% | 2,952,371 |
Source
Related
- 4d Molecular Therapeutics, Inc.
- Venrock Healthcare Capital Partners III, L.P.
- 4d Molecular Therapeutics, Inc. shareholders
- Schedule 13G/A · Venrock Healthcare Capital Partners III, L.P. · May 15, 2025
- Form 4 · Bizily Scott · Oct 20, 2026
- Form 4 · Kirn David · Oct 7, 2026
- Form 4 · Bizily Scott · Sep 22, 2026
- Form 4 · Kirn David · Sep 16, 2026
- Form 4 · Bizily Scott · Sep 3, 2026